A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Clinical trial NCT06181435 · COMPLETED

Trial details

NCT number: NCT06181435
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Dermatitis Atopic

Start date: 2023-12-21
Primary completion: 2025-11-25
Enrollment: 589

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.